Serum miR‐92a‐1 is a novel diagnostic biomarker for colorectal cancer
Authors:
Open Access
- 20 June 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (15) , 8363-8367
Abstract
Colorectal cancer (CRC) is one of the most common cancers worldwide, with high mortality. Abnormally expressed microRNAs (miRNAs) are considered novel biomarkers in cancer diagnosis. The aim of this study was to investigate the diagnostic value of miR‐92a‐1 in patients with CRC. Serum samples were collected from 148 patients pathologically diagnosed with CRC and 68 gender‐ and age‐matched healthy volunteers. Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to measure serum miR‐92a‐1 level. Relationship between miR‐92a‐1 and clinicopathological features of CRC cases was analysed via chi‐square test. Receiver operating characteristic (ROC) curve was plotted to estimate the diagnostic value of miR‐92a‐1 in CRC. Serum miR‐92a‐1 was significantly up‐regulated in CRC patients compared with healthy individuals (P < .001). Moreover, miR‐92a‐1 expression was correlated with TNM stage (P = .02), histological stage (P = .003), lymph node metastasis (P = .003) and distant metastasis (P < .001). ROC analysis showed that the area under the ROC curve (AUC) was 0.914, suggesting high diagnostic accuracy of miR‐92a‐1 in ROC. The optimal cut‐off value was 1.485, with a sensitivity of 81.8% and a specificity of 95.6%. MiR‐92a‐1 is increased in CRC patients and correlated with aggressive clinical characteristics. Serum miR‐92a‐1 may be a potential diagnostic biomarker for CRC.Keywords
This publication has 37 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive reviewEMBO Molecular Medicine, 2012
- A Functional Variant in MicroRNA-196a2 Is Associated with Susceptibility of Colorectal Cancer in a Chinese PopulationArchives of Medical Research, 2011
- Targeting microRNAs in cancer: rationale, strategies and challengesNature Reviews Drug Discovery, 2010
- Role of Adjuvant Therapy After Resection of Colorectal Cancer Liver MetastasesJournal of Clinical Oncology, 2010
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia MeridionaleJournal of Clinical Oncology, 2005
- A microRNA polycistron as a potential human oncogeneNature, 2005
- MicroRNAs: small RNAs with a big role in gene regulationNature Reviews Genetics, 2004
- The colorectal adenoma–carcinoma sequenceBritish Journal of Surgery, 2002